



The Global Language of Business

# Shipment Notification Business Message Standard (BMS)

*Release 3.7, Ratified, Mar 2025*



## Document Summary

Document Item	Current Value
Document Name	Shipment Notification Business Message Standard (BMS)
Document Date	Mar 2025
Document Version	3.7
Document Issue	
Document Status	Ratified
Document Description	

## Work Request Reference

Date of WR Submission to GSMP:	WR Submitter(s):	Refer to Work Request (WR) Number(s):

## Business Requirements Document (BRAD) Reference

BRAD Title	BRAD Issue Date	BRAD Version

## Document Change History

Date of Change	Version	Changed By	Reason for Change	Summary of Change
3-Apr-2020	BMS 3.4.2	Mark Van Eeghem	Initial Draft	Initial Draft
10-Aug-2020	BMS 3.4.2	Piergiorgio Licciardello	Changes after group revision	Changes to structure and attribute definitions.
24-Sep-2020	BMS 3.4.2	Piergiorgio Licciardello	Group revision	
29-Oct-2020	BMS 3.4.2	Piergiorgio Licciardello	Errata corrige	Class diagram update
15-Jan-2021	BMS 3.5	Miklos Bolyky	BMS Release 3.5	See summary of changes
05-Jan-2022	BMS 3.5.1	Miklos Bolyky	BMS Release 3.5.1	See summary of changes
01-Mar-2023	BMS 3.6	Miklos Bolyky	BMS Release 3.6	See summary of changes
15-Mar-2025	BMS 3.7	Miklos Bolyky	BMS Release 3.7	See summary of changes

## Disclaimer

GS1 seeks to minimise barriers to the adoption of its standards and guidelines by making the intellectual property required to implement them available, to the greatest extent possible, on a royalty-free basis, or

when necessary, under a RAND licence. Such royalty-free and RAND licences are provided pursuant to the GS1 IP Policy (available here: <https://www.gs1.org/standards/ip>), which governs the work of work group participants who contribute to drafting standards and guidelines, including this document. In addition to licences, the GS1 IP Policy provides various benefits and obligations that apply to all implementers of GS1 standards and guidelines, and all implementations of GS1 standards are subject to those terms.

Nevertheless, please note the possibility that an implementation of one or more features of this standard or guideline may be the subject of a patent or other intellectual property right that is not covered by the licences granted pursuant to the IP Policy. In addition, the licences granted under the IP Policy do not include the IP rights or claims of third parties who were not participants in the corresponding standard development work group.

Accordingly, GS1 recommends that any person or organisation developing an implementation of this standard or guideline should determine whether any patents or other intellectual property may encompass such implementation, and whether a licence under a patent or other IP right is needed. The implementer should determine the potential need for licensing in view of the details of the specific implementation being designed in consultation with that party's patent counsel.

The official versions of all GS1 standards and guidelines are provided as PDF files on GS1's online reference directory (<https://ref.gs1.org>) (the "GS1 Reference"). Any other representations of standards or guidelines in any other format (e.g., web pages) are provided for convenience and descriptive purposes only, and in the event of a conflict, the GS1 Reference document shall govern.

THIS DOCUMENT IS PROVIDED "AS IS" WITH NO WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR PARTICULAR PURPOSE, ACCURACY OR COMPLETENESS, OR ANY WARRANTY OTHERWISE ARISING OUT OF THIS DOCUMENT. GS1 disclaims all liability for any damages arising from any use or misuse of this document, whether special, indirect, consequential, or compensatory damages, and including liability for infringement of any intellectual property rights, relating to use of information in or reliance upon this document.

GS1 makes no commitment to update the information contained herein, and retains the right to make changes to this document at any time, without notice. GS1® and the GS1 logo are registered trademarks of GS1 AISBL.

# Table of Contents

<b>1</b>	<b>Business Domain View .....</b>	<b>5</b>
1.1	Introduction .....	5
1.2	References .....	5
<b>2</b>	<b>Business Context .....</b>	<b>6</b>
<b>3</b>	<b>Business Transaction View .....</b>	<b>6</b>
<b>4</b>	<b>Business Information View .....</b>	<b>8</b>
4.1	Shipment Notification .....	8
4.2	Enumerations (message specific) .....	11
4.3	Code Lists .....	11
<b>5</b>	<b>Business Message Examples .....</b>	<b>11</b>
5.1	Example 1 .....	11
<b>6</b>	<b>Implementation Considerations .....</b>	<b>12</b>
6.1	User Guide .....	12
6.2	Message Specific Considerations .....	12
<b>7</b>	<b>Summary of Changes .....</b>	<b>12</b>
7.1	BMS Release 3.4.2 .....	12
7.2	BMS Release 3.5 .....	12
7.3	BMS Release 3.5.1 .....	12
7.4	BMS Release 3.6 .....	12
7.4	BMS Release 3.7 .....	12
<b>8</b>	<b>Appendices .....</b>	<b>13</b>
<b>9</b>	<b>Acknowledgements .....</b>	<b>13</b>
9.1.1	Work Group .....	13
9.1.2	Development Team Members .....	15

# 1 Business Domain View

## 1.1 Introduction

- **Purpose**

The Shipment Notification is the acknowledgment of the Shipment Request message. The Shipment Notification should be sent by the recipient once the Shipment Request message is received by the recipient. This Shipment Notification Business Message Standard is one part of a suite of documents designed to provide the detailed technical mappings to GS1 message formats for EDI messages being implemented for Clinical Trials.

The other documents in this suite are:

- Inventory Release
- Shipment Request
- Shipment Confirmation
- Despatch Advice
- Receiving Advice
- Request for Inventory Report
- Inventory Report
- Kit Status Change
- Dispensing Advice

### Scope

The scope of this work includes all messages identified in *the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline*, hereafter called '*the Guideline*', section 4.2.

### Considerations

The workgroup that developed this mapping document has ensured that the messages and associated mappings are technology and sponsor agnostic.

It is important that organisations implementing electronic business messaging in line with this guideline undertake an appropriate assessment to ensure that the blinding status of the trial is respected in the messages exchanged.

Messaging communication with transport providers/couriers/carriers are out of scope because there are already electronic processes in place and altering them would not add value.

## 1.2 References

Reference Name	Description
<a href="#">GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline</a> ,	The guideline detailing the business requirement of the clinical trials context, both in terms of process design and data set shared between the actors


## 2 Business Context

Context Category	Value(s)
Industry	Healthcare, Pharmaceuticals & Medical Devices
Geopolitical	All
Product	All
Process	Clinical Trials
System Capabilities	GS1 System
Official Constraints	None

## 3 Business Transaction View

### Business Process Participants

As detailed in *the Guideline*, section 4.1, the diagram and table below provide an overview of the main actors involved in the process.



**Table 3-1** Roles and responsibilities

Role	Responsibility in process
Manufacturer/sponsor	Has overall responsibility for the trial, and produces the Investigational Product (IP)
Contract Manufacturing Organisation (CMO)	Manufactures and may package IP and IP kits at the direction of the manufacturer/sponsor
Packaging site	Packages and labels the IP and IP kits
Distributor (with warehouse)	Warehouses and distributes the IP kits as needed to the sites
Carrier (transporting the goods)	Logistics provider moving the IP kits at the request of other stakeholders
Clinical trial site	The healthcare provider location where the trial is conducted and dispensing to the patient typically occurs
Return facility	Responsible for receipt of any IP kits returned from trial sites

Distribution Management Entity (DME)	A term used to identify the system(s) managing, distribution, and disposition of clinical supplies. In many cases this is the interactive technology IRT system, portal, , a set of tools or different databases used to share information during a clinical trial, etc.
--------------------------------------	--

### Use Case Diagram

N/A

### Use Case Description

Below is the use case detailed in *the Guideline*, section 7.3.2

Performance goals	To ensure an accurate and timely acknowledgement that the shipment request has been received.								
Preconditions	Unique identification of locations, trade items and logistics units will be undertaken. Correct identification of sender (Ship From) and receiver (Ship To) are in place.								
Post conditions	None identified								
Scenario	<p>Begins when the Ship From party sends a notification to the requestor of the shipment request (UC-1).</p> <p>Continues with...</p> <table><tr><th>Step #</th><th>Actor</th><th>Activity step</th></tr><tr><td>1</td><td>Requestor</td><td>Receives the shipment notification.</td></tr></table> <p>Ends when the Requestor provides the shipment notification.</p>			Step #	Actor	Activity step	1	Requestor	Receives the shipment notification.
Step #	Actor	Activity step							
1	Requestor	Receives the shipment notification.							
Alternative scenario	Not applicable								
Related requirements	None identified								
Related rules	None identified								

### Activity Diagram(s)

Not applicable

### Sequence Diagram(s)

Not applicable




## **4 Business Information View**

### **4.1 Shipment Notification**

**Class diagram**





## Report

The content of the ShipmentNotification class, its structure and component definitions can be accessed in the GS1 Navigator:

[Navigator link](#)



Content	Attribute / Role	Datatype / Secondary class	Multiplicity	Definition	Constraints
<b>ShipmentNotification</b>					
ASSOCIATION	GENERALIZATION	EcomDocument	1..1	Shipment Notification is the acknowledgment of the Shipment Request message. It should be sent by the recipient as soon as possible once the Shipment Request message is received by the recipient.	
ASSOCIATION	shipmentNotificationIdentification	Ecom_EntityIdentification	1..1	The identification of the Shipment Notification message	
ASSOCIATION	shipmentRequestIdentification	Ecom_EntityIdentification	1..1	The reference to the request originating the shipment	
ASSOCIATION	sender	Ecom_PartyIdentification	0..1	The entity in charge of the shipment	
ASSOCIATION	receiver	Ecom_PartyIdentification	0..1	The entity generating the referred shipment request	
ATTRIBUTE	protocolID	string	1..1	The unique identification of the protocol	{1..20}
ATTRIBUTE	protocolOwner	GLN	1..1	The protocol sponsor	

## 4.2 Enumerations (message specific)

Not applicable.

## 4.3 Code Lists

Class	Codelist	Navigator Link



**Note:** Refer to the GS1 Navigator (Navigator) for the code values.

# 5 Business Message Examples

## 5.1 Example 1

Below is an example of acknowledgement that the shipment request has been received.

### Party Information

GS1 Global Location Number	Party Type
9520000000028	sender
9520000000011	receiver
9520000000004	Protocol owner

### Message Example 1

Attribute	Value
<b>ShipmentNotification</b>	
<b><i>shipmentNotificationIdentification</i></b>	
entityIdentification	12
<b><i>shipmentRequestIdentification</i></b>	
entityIdentification	523
<b><i>sender</i></b>	
GLN	9520000000028
<b><i>receiver</i></b>	
GLN	9520000000011
protocolID	PROT1
protocolOwner	9520000000004

## 6 Implementation Considerations

### 6.1 User Guide

All implementation considerations are discussed in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#).

### 6.2 Message Specific Considerations

Any message specific considerations are discussed in the above guideline.

## 7 Summary of Changes

Any change in the GS1 standards is done based on the Work Request (WR) submitted by the GS1 User Companies or Member Organisations. All Work Requests are documented in the Work Request system available on the GS1 website: <http://wr.gs1.org>. The system is accessible to registered users. New visitors need to register first, to be able to access it. WRs can be searched by the number referenced in tables below, see: Search Work Requests. The number starts with the two last digits of the year when it was submitted, followed by the consecutive number within that year.



**Note:** WRs submitted earlier than February 2012 should be searched in Old Change Requests.

### 7.1 BMS Release 3.4.2

Change	Associated CR Number
<ul style="list-style-type: none"> <li>Initial Draft</li> </ul>	

### 7.2 BMS Release 3.5

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

### 7.3 BMS Release 3.5.1

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

### 7.4 BMS Release 3.6

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

### 7.4 BMS Release 3.7

Change	Associated CR Number
<ul style="list-style-type: none"> <li>Changed the cardinality of <b>sender</b> and <b>receiver</b> from 1..1 to 0..1</li> </ul>	WR-24-000186

## 8 Appendices

Not Applicable

## 9 Acknowledgements

### 9.1.1 Work Group

Function	Name	Company / organisation
<b>WG chair</b>	Olivia Chauvel (Chair)	CH Victor Dupouy
<b>WG chair</b>	Pierre Fernandez- Barbereau (Chair)	SANOFI
<b>WG chair</b>	Hans von Steiger (Chair)	Pfizer
<b>WG member</b>	Jean-Michel Descoutures	International Hospital Federation (IHF)
<b>WG member</b>	Feargal Mc Groarty	St. James's Hospital
<b>WG member</b>	Vincent Puglia	endpoint clinical
<b>WG member</b>	Mike Meakin	DHL
<b>WG member</b>	Sylvain Alberola	SANOFI
<b>WG member</b>	Céline Bordes- Terrier	CREAPHARM
<b>WG member</b>	Giedré Bracaité	F. Hoffmann-La Roche Ltd.
<b>WG member</b>	Doris Cadart	SANOFI
<b>WG member</b>	Pedro Carvalho	Ipsen
<b>WG member</b>	Robert Giguere	AbbVie
<b>WG member</b>	Nicolas Gryspeert	F. Hoffmann-La Roche Ltd.
<b>WG member</b>	Michael Hoefling	Boehringer Ingelheim Pharma GmbH & Co.KG
<b>WG member</b>	Richard Hwang	Pfizer
<b>WG member</b>	Marco Inserra	CSL Behring GmbH
<b>WG member</b>	Jason James	Bristol-Myers Squibb
<b>WG member</b>	Matthias Kallmeyer	Boehringer Ingelheim Pharma GmbH & Co.KG
<b>WG member</b>	Nicolas Le Rudlier	CREAPHARM
<b>WG member</b>	Yann Montcourt	Ipsen
<b>WG member</b>	Barry Moore	GlaxoSmithKline
<b>WG member</b>	Marianne Perdrijat	DBV TECHNOLOGIES
<b>WG member</b>	Amy Rupp	CSL Behring GmbH
<b>WG member</b>	Amanda Scott	Biogen
<b>WG member</b>	Jodi Smith-Gick	Eli Lilly and Company
<b>WG member</b>	Richard Austin	PAREXEL International GmbH
<b>WG member</b>	Nick Bobrinskoy	nCoup, Inc.
<b>WG member</b>	Arpad Boldis	Deloitte
<b>WG member</b>	Robert Celeste	Center for Supply Chain Studies

Function	Name	Company / organisation
<b>WG member</b>	Dilip Daswani	Qliktag Software (formally Zeebric LLC)
<b>WG member</b>	Andreas Geissler	PAREXEL International GmbH
<b>WG member</b>	Mark Hanly	Almac Clinical Technologies
<b>WG member</b>	Mike Hutton	Almac Clinical Technologies
<b>WG member</b>	Kelly Knowles	Bracket Global
<b>WG member</b>	Jitendra Kumar	Thermo Fisher Scientific
<b>WG member</b>	Cherish Lallone	McCreadie Group
<b>WG member</b>	Charlotte Meuldermans	Deloitte
<b>WG member</b>	Fabiana Monaco	PAREXEL International GmbH
<b>WG member</b>	Josef Preishuber-Pflügl	CISC Semiconductor GmbH
<b>WG member</b>	Theodora Sarver	Almac Clinical Technologies
<b>WG member</b>	Michael schlesselman	McCreadie Group
<b>WG member</b>	Colette Thorold	PAREXEL International GmbH
<b>WG member</b>	Elizabeth Waldorf	TraceLink
<b>WG member</b>	Stefan Zietze	PAREXEL International GmbH
<b>WG member</b>	Andrea Zobel	PAREXEL International GmbH
<b>WG member</b>	Shreenidhi Bharadwaj	Syndigo
<b>WG member</b>	Tony Zhang	Syndigo
<b>WG member</b>	Richard Perkins	eClinical Forum
<b>WG member</b>	Olivier Mary	COLCA Medical & Scientific
<b>WG member</b>	Preedee Chenhansa	Tenthpin
<b>WG member</b>	Poppy Abeto Kiese	GS1 Austria
<b>WG member</b>	Andrea Arozamena	GS1 Mexico
<b>WG member</b>	Mahdi Barati	GS1 Iran
<b>WG member</b>	Jiraporn Chalermjirarat	GS1 Thailand
<b>WG member</b>	Shawn Chen	GS1 Thailand
<b>WG member</b>	Mignone Cheng	GS1 Hong Kong, China
<b>WG member</b>	Luiz Costa	GS1 Brasil
<b>WG member</b>	Sandra Couto	GS1 Canada
<b>WG member</b>	Jesper Kervin Franke	GS1 Denmark
<b>WG member</b>	Stefan Gathmann	GS1 Ireland
<b>WG member</b>	Nicole Golestani	GS1 Canada
<b>WG member</b>	Rami Habbal	GS1 UAE
<b>WG member</b>	Michaela Hähn	GS1 Germany
<b>WG member</b>	Christine Horvath-Hanko	GS1 Hungary

Function	Name	Company / organisation
<b>WG member</b>	Anna Klapper	GS1 Germany
<b>WG member</b>	Catherine Koetz	GS1 Australia
<b>WG member</b>	Anne-Claire Krid	GS1 France
<b>WG member</b>	Camille Labeaune	GS1 France
<b>WG member</b>	Ildikó Lieber	GS1 Hungary
<b>WG member</b>	Valerie Marchand	GS1 France
<b>WG member</b>	Adrien Molines	GS1 France
<b>WG member</b>	Zubair Nazir	GS1 Canada
<b>WG member</b>	Alice Nguyen	GS1 Vietnam
<b>WG member</b>	James Perng	GS1 Chinese Taipei
<b>WG member</b>	James Perng	GS1 Chinese Taipei
<b>WG member</b>	Paul Reid	GS1 UK
<b>WG member</b>	Sylvia Reingardt	GS1 Germany
<b>WG member</b>	Sue Schmid	GS1 Australia
<b>WG member</b>	Julian Sin	GS1 Hong Kong, China
<b>WG member</b>	Mig Smith	GS1 UK
<b>WG member</b>	Peter Sturtevant	GS1 US
<b>WG member</b>	Flora Sue	GS1 China
<b>WG member</b>	Sarah Torrance	GS1 UK
<b>WG member</b>	Koichi Uemura	GS1 Japan
<b>WG member</b>	Amber Walls	GS1 US
<b>WG member</b>	Connie Wong	GS1 Canada
<b>WG member</b>	Pete Alvarez	GS1 Global Office
<b>WG member</b>	Jean-Luc Champion	GS1 Global Office
<b>WG member</b>	Steven Keddle	GS1 Global Office
<b>WG member</b>	Neil Piper	GS1 Global Office
<b>WG member</b>	Greg Rowe	GS1 Global Office
<b>WG member</b>	Tania Snioch	GS1 Global Office

### 9.1.2 Development Team Members

Function	Name	Organisation
GSMP Process Lead	David Buckley	GS1 Global Office
Technical Development Lead	Miklos Bolyky	GS1 Global Office
Peer Review	Mark Van Eeghem	GS1 Global Office